Alnylam Pharmaceuticals
ALNY
#637
Rank
โ‚น3.799 T
Marketcap
โ‚น28,460
Share price
-1.02%
Change (1 day)
15.20%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): โ‚น346.28

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is โ‚น362.63. In 2025 the company made an earnings per share (EPS) of โ‚น172.22.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น346.28101.06%
2025โ‚น172.22
2023-โ‚น337.75-62%
2022-โ‚น888.8729.03%
2021-โ‚น688.90-3.36%
2020-โ‚น712.82-8.48%
2019-โ‚น778.847.67%
2018-โ‚น723.3439.74%
2017-โ‚น517.6312.94%
2016-โ‚น458.3138.84%
2015-โ‚น330.10-32.88%
2014-โ‚น491.80259.44%
2013-โ‚น136.82-31.25%
2012-โ‚น199.01

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
โ‚น671.67 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น244.91-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น4,069 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น796.06-319.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น69.85-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น22.96-106.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น131.08-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
โ‚น33.49-90.77%๐Ÿ‡บ๐Ÿ‡ธ USA